Sorrento Therapeutics, Inc.
SRNE
$0.001
$0.000111.11%
| Weiss Ratings | SRNE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | -- | |||
| Risk Index | -- | |||
| Risk Grade | -- | |||
| Reward Grade | -- | |||
| Rating Factors | SRNE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | -- | |||
| Efficiency Index | -- | |||
| Solvency Index | -- | |||
| Total Return Index | -- | |||
| Volatility Index | -- | |||
| Beta / Standard Deviation | SRNE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -1.23 | |||
| Price History | SRNE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -16.67% | |||
| 30-Day Total Return | 100.00% | |||
| 60-Day Total Return | 100.00% | |||
| 90-Day Total Return | -33.33% | |||
| Year to Date Total Return | 25.00% | |||
| 1-Year Total Return | -96.55% | |||
| 2-Year Total Return | -99.71% | |||
| 3-Year Total Return | -99.95% | |||
| 5-Year Total Return | -99.96% | |||
| 52-Week High % Change | -98.94% | |||
| 52-Week Low % Change | 1,263.64% | |||
| Price | SRNE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.08 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Dec 30, 2024 | |||
| 52-Week High Price (Date) | Apr 15, 2024 | |||
| Valuation | SRNE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 489.34K | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.10 | |||
| Earnings Per Share Growth | -28.44% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.01 | |||
| Price/Book (Q) | 0.00 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | SRNE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 551.28M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | 0.00% | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | SRNE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 203 4100 | |||
| Address | 4955 Directors Place San Diego, CA 92121 | |||
| Website | www.sorrentotherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2006 | |||
| Profitability | SRNE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -553.16% | |||
| Profit Margin | -852.80% | |||
| Management Effectiveness | SRNE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -40.81% | |||
| Return on Equity | -- | |||
| Income Statement | SRNE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 64.27M | |||
| Total Revenue (TTM) | 64.27M | |||
| Revenue Per Share | $0.12 | |||
| Gross Profit (TTM) | -157.47M | |||
| EBITDA (TTM) | -341.60M | |||
| EBIT (TTM) | -355.52M | |||
| Net Income (TTM) | -548.10M | |||
| Net Income Avl. to Common (TTM) | -548.10M | |||
| Total Revenue Growth (Q YOY) | 31.10% | |||
| Earnings Growth (Q YOY) | 50.55% | |||
| EPS Diluted (TTM) | -1.10 | |||
| EPS Diluted Growth (Q YOY) | 68.20% | |||
| Balance Sheet | SRNE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 80.64M | |||
| Cash Per Share (Q) | $0.15 | |||
| Total Current Assets (Q) | 133.11M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -197.96M | |||
| Current Ratio (Q) | 0.405 | |||
| Book Value Per Share (Q) | -$0.38 | |||
| Total Assets (Q) | 456.69M | |||
| Total Current Liabilities (Q) | 328.87M | |||
| Total Debt (Q) | 207.60M | |||
| Total Liabilities (Q) | 654.65M | |||
| Total Common Equity (Q) | -205.11M | |||
| Cash Flow | SRNE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -11.58M | |||
| Cash from Financing (TTM) | 246.59M | |||
| Net Change in Cash (TTM) | -596.00K | |||
| Levered Free Cash Flow (TTM) | -61.79M | |||
| Cash from Operations (TTM) | -234.63M | |||
